IL2-receptor antagonist (basiliximab) induction therapy is associated with lower morbidity and mortality in renal transplant recipients

Transplant Proc. 2003 Feb;35(1):195. doi: 10.1016/s0041-1345(02)03980-5.
No abstract available

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Antibodies, Monoclonal / therapeutic use*
  • Basiliximab
  • Drug Therapy, Combination
  • Female
  • Graft Rejection / epidemiology
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Kidney Transplantation / adverse effects
  • Kidney Transplantation / immunology*
  • Male
  • Morbidity
  • Postoperative Complications / classification
  • Postoperative Complications / epidemiology
  • Postoperative Complications / prevention & control
  • Recombinant Fusion Proteins*
  • Retrospective Studies

Substances

  • Antibodies, Monoclonal
  • Immunosuppressive Agents
  • Recombinant Fusion Proteins
  • Basiliximab